Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors

Transplant Immunology
H T HassanA R Zander

Abstract

Recombinant human granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem/progenitor cells (PBPC) have replaced bone marrow (BM) harvests for autologous transplantation after myeloablative therapy in cancer patients. G-CSF-mobilized PBPC from healthy donors contain one log excess of T lymphocytes representing a potential risk for graft-versus-host disease (GVHD). However, recent pilot clinical studies of G-CSF-mobilized allogeneic PBPC transplantation have shown rapid haematological recovery and no severe acute GVHD except in a very few cases. Therefore, the risk of inducing severe acute GVHD is not as high as was expected during the pioneering period of allogeneic PBPC transplantation. The present study was performed to address the possible reasons for the rapid haematological recovery and the absence of severe acute GVHD observed after allogeneic PBPC transplantation by comparing the contents and subsets of CD3+ and CD34+ G-CSF-mobilized PBPC (n = 31) with those of BM (n = 26) allografts from healthy adult donors. The present results revealed that the phenotypic profiles of CD3+ and CD34+ cells differ between PBPC and BM allografts. The single PBPC leukapheresis product contained 10 times more mononuclea...Continue Reading

Citations

Jul 16, 2003·International Immunopharmacology·James E Talmadge
Feb 4, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S TerakuraUNKNOWN Nagoya Blood and Marrow Transplantation Group
Mar 26, 2014·Cancers·Peter R C Gascoyne, Sangjo Shim
Nov 14, 1997·Journal of Biochemical and Biophysical Methods·N G GreenJ J Milner
Jan 15, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Junya KandaWael Saber
Apr 29, 2015·Bone Marrow Transplantation·U DeotareJ H Lipton
Mar 22, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kavita RajPaul O'Donnell
Jun 21, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·M OstronoffC Tagliari
Oct 14, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Joseph PidalaBenjamin Djulbegovic
Dec 20, 2011·Blood Reviews·Anna Rita MigliaccioCarolyn Whitsett
Oct 11, 2005·Critical Reviews in Oncology/hematology·Wolfgang KernSusanne Schnittger
May 26, 2018·Bone Marrow Transplantation·Katharina FleischhauerBronwen E Shaw

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.